Atorvastatin and insulin glargine are two examples that mention obesity in the package insert.53,57 One study found that only
27% of 84 injectable medications contained dosing information with weight descriptors in
the package insert or pivotal trials.58 Reporting weight distributions, especially in diseases
common in obese individuals, is needed to provide clinicians with the necessary tools to
determine optimal doses in obese patients.